EYPT · TickerCove

EYPTEyePoint Pharmaceuticals, Inc.Healthcare · Biotechnologyas of 2026-09-25

Horizon

Issued 2026-09-25 at $3.62 · now $3.62 (2026-09-25, +0.0% since)

Based on its own history, a month from the 2026-09-25 close, EYPT has typically landed between $2.42 and $5.44 — a range of −33.1% to +50.4% from the issuance price $3.62.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.

Actual close
Typical path (median)
Middle 50% of outcomes
90% range

5,009 overlapping 1 month windows · 2006-09-26 – 2026-08-26 · basis climatology · forecast (batch). Base rate up 53.7% (90% CI 51.5–55.9%, ≈1,391 obs). Not a call on this stock — we have no evidence its odds differ.

The cone is anchored at the 2026-09-25 issuance close ($3.62) — the price the forecast resolves against on 2026-10-26, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

52-week range$3.62 · 1% of range

$3.45 low$18.85 high

Trailing 52 weeks to 2026-09-25 — factual context, not a signal.

Base rate up · monthiClimatology base rate that a US-listed stock rises over a month, with its 90% CI and ≈1,391 effective observations. Not a call on this stock — we have no evidence its odds differ.

53.7%

90% CI 51.5%–55.9%

Distribution · month iiThe price-anchored range: typical move (median), and the p90 downside/upside — 90% of similar periods stayed inside these. Ranges, not a prediction of direction.

−3.3%

typical move · IQR 37.0%

−33.1%worst (p90)+50.4%best (p90)

Insider convictioniOpen-market common-stock purchases by company insiders in the last 90 days (grants and option exercises excluded). Historical tendency, not advice — detail below.

conviction buys

0 open-market sales

Congress disclosuresiRecent disclosed congressional trades for this company. Purchase clusters (≥2 members buying within 90 days) historically preceded a modestly higher forward return (+32 bp/mo in 2022–2026, +45 bp/mo in 2015–2021) — a descriptive tendency, not a forecast input. Detail below.

0 buys · 0 sells · 0 members

cluster tilt persisted, ~halved after 2021

Where EYPT has typically landed a month from the 2026-09-25 close of $3.62 — the range is history, not a prediction.

now $3.62 (+0.0%)
typical $3.5 (-3.3%)
middle 50% $2.83–$4.17
90% range $2.42–$5.44

Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 5,009 windows spanning 2006-09-26 to 2026-09-25. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.

Start	Return	Max drop	Max rise
3 worst
2026-08-14	−75.2%	−75.2%	+0.0%
2011-10-21	−74.0%	−74.0%	+12.3%
2011-10-24	−71.6%	−74.0%	+12.3%
3 best
2023-11-22	+293.7%	+0.0%	+293.7%
2023-11-24	+293.0%	−0.8%	+293.0%
2023-11-27	+283.1%	−1.0%	+292.4%

5,009 overlapping windows · 2006-09-26 – 2026-09-25 · not cherry-picked

Pending catalysts

October 2026 — Trial primary completion: Phase 3 primary completion: A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 (source, as of 2026-08-14)
October 2027 — Trial primary completion: Phase 3 primary completion: COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (source, as of 2026-08-14)
October 2027 — Trial primary completion: Phase 3 primary completion: CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (source, as of 2026-08-14)

Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.

Seasonality · by month i

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~20 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.

Jan

60%

+5.4%

n=20

Feb

40%

+0.6%

n=20

Mar

35%

−0.5%

n=20

Apr

60%

+17.9%

n=20

May

40%

−0.2%

n=20

Jun

40%

−1.2%

n=20

Jul

60%

+4.8%

n=20

Aug

35%

−5.1%

n=20

Sep

35%

+0.1%

n=20

Oct

35%

−4.5%

n=20

Nov

50%

−4.0%

n=20

Dec

35%

+11.4%

n=20

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Date	Person	Role	Action	Shares @ price	Value	Ownership Δ	vs S&P 1m	vs S&P 6m	Owned after	Filing
2026-08-18	Zaderej Karen L.	director	Purchase	10,600 @ $4.93	$52K	+27.5% of holding	−26.2%	not yet — horizon still open	49,100	Form 4 · filed same day
2026-06-30	Ribeiro Ramiro	officer	Sale	2,438 @ $15.02	$37K	−100.0% of holding	−9.4%	not yet — horizon still open	0	Form 4 · filed 2 days after the trade
2026-06-30	Ribeiro Ramiro	officer	Sale	2,437 @ $15.00	$37K	−50.0% of holding	−9.4%	not yet — horizon still open	2,438	Form 4 · filed 2 days after the trade
2026-04-17	Ribeiro Ramiro	officer	Sale	2,437 @ $15.00	$37K	−100.0% of holding	−25.6%	not yet — horizon still open	0	Form 4 · filed 3 days after the trade
2026-03-16	Duker Jay S.	director	Purchase	1,500 @ $13.15	$20K	+1.5% of holding	+3.9%	−86.3%	100,665	Form 4 · filed same day
2026-03-04	Ribeiro Ramiro	officer	Sale	2,438 @ $17.87	$44K	−100.0% of holding	−21.5%	−85.7%	0	Form 4 · filed 1 day after the trade
2026-02-17	Ribeiro Ramiro	officer	Sale	2,437 @ $15.00	$37K	−100.0% of holding	−5.4%	−76.3%	0	Form 4 · filed 1 day after the trade
2026-01-05	Ribeiro Ramiro	officer	Sale	42,544 @ $17.10	$727K	−100.0% of holding	−29.0%	−28.6%	0	Form 4 · filed 2 days after the trade
2025-12-04	Cormorant Asset Management, LP	other	Sale	60,000 @ $15.70	$942K	−0.7% of holding	−0.5%	−40.1%	8,265,000	Form 4 · filed 4 days after the trade
2025-12-04	Lurker Nancy	director	Sale	9,300 @ $15.11	$140K	−4.3% of holding	−0.5%	−40.1%	206,547	Form 4 · filed 1 day after the trade
2025-11-28	Lurker Nancy	director	Sale	500 @ $14.95	$7K	−0.2% of holding	+19.8%	−27.3%	215,847	Form 4 · filed 3 days after the trade
2025-11-26	Lurker Nancy	director	Sale	200 @ $14.95	$3K	−0.1% of holding	+21.6%	−23.3%	216,347	Form 4 · filed 5 days after the trade
2025-11-11	Ribeiro Ramiro	officer	Sale	2,722 @ $11.61	$32K	−100.0% of holding	+37.3%	+3.5%	0	Form 4 · filed 1 day after the trade
2025-05-19	Zaderej Karen L.	director	Purchase	5,000 @ $5.99	$30K	+15.9% of holding	+45.8%	+102.9%	36,500	Form 4 · filed same day
2025-05-16	Zaderej Karen L.	director	Purchase	5,000 @ $5.81	$29K	+18.9% of holding	+43.2%	+75.2%	31,500	Form 4 · filed 3 days after the trade
2025-05-15	Zaderej Karen L.	director	Purchase	5,000 @ $5.47	$27K	+23.3% of holding	+53.5%	+86.8%	26,500	Form 4 · filed same day
2025-05-14	Zaderej Karen L.	director	Purchase	5,000 @ $5.42	$27K	+30.3% of holding	+62.9%	+101.4%	21,500	Form 4 · filed 1 day after the trade
2024-08-21	ANDO GORAN	director	Purchase	5,000 @ $7.95	$40K	+61.3% of holding	−3.2%	−41.9%	13,150	Form 4 · filed same day
2024-08-20	DICICCO WENDY F	director	Purchase	2,567 @ $7.79	$20K	+34.7% of holding	+16.7%	−28.4%	9,967	Form 4 · filed 1 day after the trade
2024-08-19	Zaderej Karen L.	director	Purchase	12,500 @ $7.98	$100K	+312.5% of holding	+11.9%	−29.8%	16,500	Form 4 · filed 2 days after the trade
2024-08-16	Lurker Nancy	director	Purchase	3,173 @ $7.88	$25K	+3.4% of holding	+9.1%	−29.7%	97,635	Form 4 · filed 4 days after the trade
2024-07-12	GUYER DAVID R	director	Sale	11,625 @ $10.06	$117K	−86.3% of holding	−14.3%	−29.5%	1,850	Form 4 · filed 4 days after the trade
2024-06-03	GUYER DAVID R	director	Sale	11,625 @ $10.30	$120K	−75.9% of holding	−17.6%	−26.4%	3,700	Form 4 · filed 1 day after the trade
2024-05-14	GUYER DAVID R	director	Sale	11,625 @ $12.65	$147K	−67.7% of holding	−29.0%	−25.5%	5,550	Form 4 · filed 2 days after the trade
2024-05-06	Cormorant Asset Management, LP	other	Purchase	642,847 @ $11.70	$7.5M	+8.6% of holding	−16.1%	−6.5%	8,117,847	Form 4 · filed 2 days after the trade
2024-05-06	Cormorant Asset Management, LP	other	Purchase	207,153 @ $12.36	$2.6M	+2.6% of holding	−16.1%	−6.5%	8,325,000	Form 4 · filed 2 days after the trade
2024-04-18	Cormorant Asset Management, LP	other	Purchase	395,244 @ $17.62	$7.0M	+5.7% of holding	−38.3%	−53.6%	7,288,479	Form 4 · filed 4 days after the trade
2024-04-18	Cormorant Asset Management, LP	other	Purchase	186,521 @ $18.90	$3.5M	+2.6% of holding	−38.3%	−53.6%	7,475,000	Form 4 · filed 4 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

183 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

Date	Person	Role	Action	Shares	Owned after	Filing
2026-08-20	Elston George	officer	Gift	64,953	32,517	Form 4
2026-08-20	Elston George	officer	Gift	64,953	64,953	Form 4
2026-08-20	Elston George	officer	Other acquisition	5,000	25,000	Form 4
2026-08-20	Elston George	officer	Other acquisition	5,000	96,691	Form 4
2026-07-10	Duker Jay S.	director	Withheld for tax	8,059	9,594	Form 4
2026-07-10	Duker Jay S.	director	Option exercise	16,667	0	Form 4
2026-07-10	Duker Jay S.	director	Option exercise	16,667	17,653	Form 4
2026-06-30	Ribeiro Ramiro	officer	Option exercise	2,438	4,875	Form 4
2026-06-30	Ribeiro Ramiro	officer	Option exercise	2,437	2,437	Form 4
2026-06-30	Ribeiro Ramiro	officer	Option exercise	2,438	75,563	Form 4
2026-06-30	Ribeiro Ramiro	officer	Option exercise	2,437	78,001	Form 4
2026-05-25	Elston George	officer	Withheld for tax	3,627	91,691	Form 4
2026-05-25	Elston George	officer	Option exercise	7,500	0	Form 4
2026-05-25	Elston George	officer	Option exercise	7,500	95,318	Form 4
2026-04-17	Ribeiro Ramiro	officer	Option exercise	2,437	2,437	Form 4
2026-04-17	Ribeiro Ramiro	officer	Option exercise	2,437	80,438	Form 4
2026-03-23	Duker Jay S.	director	Other acquisition	76,766	177,431	Form 4
2026-03-23	Duker Jay S.	director	Other acquisition	76,766	986	Form 4
2026-03-23	Duker Jay S.	director	Other acquisition	97,500	82,500	Form 4
2026-03-23	Duker Jay S.	director	Other acquisition	97,500	97,500	Form 4
2026-03-23	Duker Jay S.	director	Other acquisition	52,500	7,800	Form 4
2026-03-23	Duker Jay S.	director	Other acquisition	52,500	52,500	Form 4
2026-03-04	Ribeiro Ramiro	officer	Option exercise	2,438	2,438	Form 4
2026-03-04	Ribeiro Ramiro	officer	Option exercise	2,438	82,875	Form 4
2026-03-02	Elston George	officer	Gift	5,000	30,000	Form 4
2026-03-02	Elston George	officer	Gift	5,000	87,818	Form 4
2026-02-17	Ribeiro Ramiro	officer	Option exercise	2,437	2,437	Form 4
2026-02-17	Ribeiro Ramiro	officer	Option exercise	2,437	85,313	Form 4
2026-01-06	Duker Jay S.	director	Withheld for tax	10,054	77,752	Form 4
2026-01-06	Elston George	officer	Withheld for tax	4,487	91,852	Form 4
2026-01-06	Lurker Nancy	director	Option exercise	75,133	0	Form 4
2026-01-06	Elston George	officer	Option exercise	15,285	96,339	Form 4
2026-01-06	Duker Jay S.	director	Option exercise	20,793	0	Form 4
2026-01-06	Duker Jay S.	director	Option exercise	20,793	87,806	Form 4
2026-01-06	Elston George	officer	Option exercise	15,285	0	Form 4
2026-01-06	Lurker Nancy	director	Option exercise	75,133	294,346	Form 4
2026-01-05	Duker Jay S.	director	Withheld for tax	14,505	67,013	Form 4
2026-01-05	Ribeiro Ramiro	officer	Option exercise	29,250	42,544	Form 4
2026-01-05	Elston George	officer	Withheld for tax	4,403	81,054	Form 4
2026-01-05	Elston George	officer	Option exercise	15,000	15,000	Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Resolves in i

27d remaining

2026-09-2610% elapsed2026-10-26

Logged immutably 2026-09-26; scored automatically on 2026-10-26 — no edits, ever.

Earnings & context analysis

These panels are being prepared. They are generated by multiple language models, checked, and stored before display — never written live for a page view. Until a model panel has been generated and reviewed for a company, nothing is shown here, honestly, rather than a placeholder.

Calibration i

Every forecast is logged when made and scored when the month is up. The record is shown from the day it starts — young and honest.

How scoring works →

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.

Pending catalysts

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

Reported insider & political trades

Congressional disclosures

Seasonality · by month i